Cosmetic composition containing ceramide-containing lipid particles

Abstract

To provide a composition for cosmetic including ceramide-containing lipid particles which is excellent in dispersion stability and use feeling.SOLUTION: A composition for cosmetic including ceramide-containing lipid particles which contains phospholipid, cholesterol, lysophospholipid and ceramide, has a volume average particle diameter of 10nm or more and 600nm or less, and polydispersity of 0.50 or less.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a cosmetic composition containing ceramide-containing lipid particles and a method for producing the same. The ceramide-containing lipid particles of the present invention can be suitably used as a cosmetic composition and a cosmetic quasi-drug. [Background technology]

[0002] Ceramides are present as a major component of intercellular lipids in the stratum corneum of the skin, and by binding to the cornified envelope, a protein lining the cell membrane, they function as a barrier to prevent moisture evaporation from the skin. As skin aging progresses, the amount of ceramides in the stratum corneum decreases, resulting in skin problems such as loss of skin moisture, exposure to external stimuli such as ultraviolet rays and chemicals, and peeling of keratinocytes, causing rough skin surfaces. It is known that applying ceramides, which are necessary for the formation and maintenance of cell membranes, to the skin can improve skin condition. Focusing on these useful functions of ceramides, studies are being conducted to incorporate ceramides into cosmetics and topical skin preparations.

[0003] For example, Patent Document 1 describes a skin cosmetic preparation with excellent skin barrier repair ability, which contains, as an intercellular lipid component, at least one selected from the group consisting of sphingolipids, higher alcohols or polyhydric alcohols or esters thereof, sterols or esters thereof, fatty acids or triglycerides thereof, and hydrocarbons; as a moisturizing component, at least one selected from the group consisting of amino acids or salts thereof, pyrrolidonecarboxylic acid or salts thereof, organic acids or salts thereof, urea, and sugars; and phospholipids.The cosmetic preparation is described as having excellent skin barrier repair ability, with excellent immediate and long-lasting effects, as well as preventive effects, and is also useful for subjects with atopic dermatitis. However, ceramides are often powders or solids at room temperature, and although stable in themselves, they are known to be poorly soluble substances that are insoluble or have low solubility in water and also have low solubility in non-polar oils. As a technique for stably blending large amounts of ceramide, Patent Document 2 describes a lipid dispersion composition that contains (a) phospholipids, (b) ceramides, and (c) polyhydric alcohols, and is characterized in that the weight ratio of components (a) to (b) is in the range of (a):(b) = 2:1 to 100:1. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Patent Publication No. 2004-168763 [Patent Document 2] JP 11-130651 Summary of the Invention [Problem to be solved by the invention]

[0005] However, it has been found that even in a dispersion in which ceramide is dispersed in a phospholipid, it is difficult to obtain a particle form. Furthermore, in order to be preferably used as a cosmetic composition, etc., there has been a demand for a cosmetic composition, etc., containing lipid particles that have good dispersion stability while taking into consideration the properties required for cosmetics, such as the feel during use. Therefore, an object of the present invention is to provide a cosmetic composition containing ceramide-containing lipid particles that are excellent in dispersion stability and feel when used. [Means for solving the problem]

[0006] The inventors conducted research in light of the above-mentioned problems and discovered that a cosmetic composition containing ceramide-containing lipid particles that contain a phospholipid, cholesterol, a lysophospholipid, and a ceramide, and that have a volume average particle diameter of 10 nm or more and 600 nm or less and a polydispersity index of 0.50 or less, has excellent dispersion stability and a pleasant feel when used, leading to the completion of the present invention. [Effects of the Invention]

[0007] According to the present invention, a cosmetic composition containing ceramide-containing lipid particles that has excellent dispersion stability and a pleasant feel when used is provided. [Brief explanation of the drawings]

[0008] [Figure 1] 1 is an image of the lipid particles of Example 1 observed with a transmission electron microscope. [Figure 2] FIG. 1 is a schematic diagram of a vertical Franz diffusion cell. [Figure 3] 1 shows the cumulative permeation amount of caffeine using a three-dimensional skin model using Example 12 and Comparative Example 10. DETAILED DESCRIPTION OF THE INVENTION

[0009] The ceramide-containing lipid particles of the present disclosure contain a phospholipid, cholesterol, a lysophospholipid, and a ceramide, and are characterized by a volume-average particle size of 10 nm or more and 600 nm or less, and a polydispersity index of 0.50 or less.

[0010] <Ceramide-containing lipid particles> The phospholipid of the present disclosure refers to a phospholipid having two acyl groups. In this specification, the term phospholipid does not include lysophospholipid, and the two are used to distinguish between them. The phospholipids of the present disclosure are not particularly limited and are compounds having a structure in which a fatty acid and a phosphate are bound to a central skeleton of glycerin or sphingosine, and further, for example, an alcohol is ester-bonded to the phosphate, such as natural phospholipids, synthetic phospholipids, and hydrogenated phospholipids in which the unsaturated carbon chain of a naturally-occurring phospholipid is saturated with hydrogen. Specific examples of phospholipids include natural phospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg yolk lecithin, and soybean lecithin; synthetic phospholipids such as dilauroylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dioleoylphosphatidylcholine, and palmitoyl-oleoylphosphatidylcholine; and hydrogenated phospholipids such as hydrogenated soybean lecithin, hydrogenated egg yolk lecithin, hydrogenated phosphatidylcholine, and hydrogenated phosphatidylserine. The phospholipid of the present disclosure is preferably a glycerophospholipid, more preferably a phosphatidylcholine in which a fatty acid is bound to two of the hydroxyl groups of glycerin, a phosphoric acid is bound to one, and choline is bound to the phosphoric acid as an alcohol. Even more preferably, hydrogenated phosphatidylcholine is used, in which the unsaturated carbon chain of the fatty acid is saturated with hydrogen. The source of the phospholipid is not particularly limited, but is preferably egg yolk phospholipid or soybean phospholipid, particularly preferably soybean phospholipid, and even more particularly preferably hydrogenated soybean phospholipid. These phospholipids can be used alone or in combination of two or more. The cholesterol of the present disclosure is a type of organic compound classified as a sterol, and is a compound widely distributed in the living bodies of mammals including humans and fish. Industrially, it can be obtained mainly by extraction and purification from wool fat. It can also be obtained from bovine and porcine cerebrospinal fluid, fish oil, squid liver oil, etc. In the present invention, cholesterol of any origin may be used, and one or more types may be used as needed. Furthermore, the cholesterol of the present disclosure may be ester-modified.

[0011] In the present disclosure, lysophospholipid refers to a phospholipid having one acyl group. In this specification, the term phospholipid does not include lysophospholipid, and the two are used to distinguish between them. The lysophospholipid of the present disclosure may be a phospholipid in which one fatty acid molecule bound to the 1st or 2nd position of glycerol has been removed by hydrolysis. The lysophospholipids of the present disclosure have chemical properties different from those of phospholipids having two-chain fatty acids. Specific examples include lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylserine, lysophosphatidylinositol, lysophosphatidic acid, lysophosphatidylglycerol, and the like, or a mixture of two or more of these. Among these lysophospholipids, lysophosphatidylcholine is preferred from the viewpoint of transparently dispersing oil in water. More preferred is hydrogenated lysophosphatidylcholine in which the unsaturated carbon chain of the fatty acid is saturated with hydrogen. The raw material for the lysophospholipid is not particularly limited, and examples thereof include soybean lysophospholipid, hydrogenated soybean lysophospholipid, egg yolk lysophospholipid, hydrogenated egg yolk lysophospholipid, etc., preferably soybean lysophospholipid, and more preferably hydrogenated soybean lysophospholipid. These lysophospholipids can be used alone or in combination as needed.

[0012] The lysophospholipid of the present disclosure may have a structure represented by the following general formula (1):

[0013] [ka] (In the formula, R represents a saturated or unsaturated aliphatic acyl group having 10 to 30 carbon atoms, and X represents a hydrogen atom or a polar group.) In general formula (1), R represents a saturated or unsaturated aliphatic acyl group having 10 to 30 carbon atoms. The saturated aliphatic acyl group having 10 to 30 carbon atoms is not particularly limited, and examples thereof include a lauroyl group, a myristoyl group, a palmitoyl group, a stearoyl group, an eicosanoyl group, a heneicosanoyl group, a docosanoyl group, a tricosanoyl group, a tetracosanoyl group, a pentacosanoyl group, a hexacosanoyl group, a heptacosanoyl group, an octacosanoyl group, a nonacosanoyl group, and a triacontanoyl group. Examples of the unsaturated aliphatic acyl group having 10 to 30 carbon atoms include monounsaturated and polyunsaturated groups, such as docosamonoenoyl, docosadienoyl, docosatrienoyl, docosatetraenoyl, docosapentaenoyl, docosahexaenoyl, tricosamonoenoyl, tricosadienoyl, oleoyl, linoleoyl, linolenoyl, and arachidonoyl groups. Preferred examples of the acyl group include palmitoyl, stearoyl, linoleoyl, oleoyl, and linolenoyl groups. X in general formula (1) represents a hydrogen atom or a polar group. Examples of the polar group include residues obtained by removing the OH group bonded to the carbon skeleton of a hydroxyl group-containing compound such as choline, ethanolamine, inositol, serine, glycerol, or ethanol. X is preferably a hydrogen atom or a residue of ethanolamine, choline, or glycerol, and more preferably glycerol.

[0014] The ceramides of the present disclosure are not limited as long as they can be used in cosmetics and the like, but can be defined as follows: That is, a series of ceramides represented as nonionic amphiphilic substances having one or more long-chain linear and / or branched alkyl or alkenyl groups in the molecule, and further having at least two hydroxyl groups and one or more amide groups (and / or amino groups), or derivatives in which a phosphatidylcholine residue or a sugar residue is bound to the hydroxyl group of the nonionic amphiphilic substance. Examples include natural ceramides such as sphingosine, phytosphingosine, and their long-chain fatty acid amides, ceramide EOS, ceramide NS, ceramide NP, ceramide NG, ceramide EOH, ceramide AS, ceramide AG, ceramide AP, ceramide AH, ceramide NH, ceramide EOP, ceramide NDS, ceramide ADS, ceramide EODS, and ceramide 3B; sphingophospholipids such as sphingomyelin and phytosphingomyelin, which are phospholipid derivatives of sphingosine and phytosphingosine; and glycosphingolipids and phytosphingolipids, such as cerebrosides and gangliosides, which are glycosides of these, and these can be used alone or in combination of two or more. In the present invention, ceramides also include synthetic ceramides, pseudoceramides, etc., but from the perspective of the advantages of the technology of the present invention, natural ceramides are preferred among these, and ceramide NS, ceramide NG, ceramide NP, ceramide 3B, and ceramide AP are particularly preferred in order to obtain excellent effects of improving rough skin and moisturizing effects.

[0015] The content of phospholipids in 100 parts by mass of lipid particles of the present disclosure is preferably 5 parts by mass or more, more preferably 30 parts by mass or more, even more preferably 45 parts by mass or more, and preferably 95 parts by mass or less, more preferably 90 parts by mass or less, and even more preferably 80 parts by mass or less, from the viewpoints of stability of the lipid particle solution, transdermal permeability, and skin barrier property.

[0016] The cholesterol content in 100 parts by mass of lipid particles of the present disclosure is preferably 1 part by mass or more, more preferably 5 parts by mass or more, even more preferably 8 parts by mass or more, preferably 35 parts by mass or less, more preferably 30 parts by mass or less, and even more preferably 25 parts by mass or less, from the viewpoint of the stability of the lipid particle solution.

[0017] The content of lysophospholipid in 100 parts by mass of lipid particles of the present disclosure is preferably 0.01 parts by mass or more, more preferably 0.1 parts by mass or more, even more preferably 1 part by mass or more, preferably 30 parts by mass or less, more preferably 28 parts by mass or less, and even more preferably 25 parts by mass or less, from the viewpoint of the stability of the lipid particle solution.

[0018] The content of ceramide in 100 parts by mass of lipid particles of the present disclosure is preferably 0.1 parts by mass or more, more preferably 1 part by mass or more, and even more preferably 3 parts by mass or more, from the viewpoint of skin barrier property, and is preferably 40 parts by mass or less, more preferably 35 parts by mass or less, and even more preferably 30 parts by mass or less, from the viewpoint of stability of the lipid particle solution.

[0019] From the viewpoint of the stability of the lipid particle solution, the content of other components in 100 parts by mass of lipid particles of the present disclosure is preferably 0 parts by mass or more, more preferably 1 part by mass or more, even more preferably 3 parts by mass or more, preferably 30 parts by mass or less, more preferably 20 parts by mass or less, and even more preferably 15 parts by mass or less.

[0020] The mass ratio of phospholipid to lysophospholipid (mass of phospholipid / mass of lysophospholipid) in the lipid particles of the present disclosure is preferably 0.1 / 1 to 40 / 1, more preferably 1 / 1 to 35 / 1, and even more preferably 3 / 1 to 30 / 1, from the viewpoint of lipid particle stability.

[0021] The content of phospholipids relative to the total amount of phospholipids and lysophospholipids in 100 parts by mass of lipid particles of the present disclosure is preferably 30 parts by mass or more, more preferably 45 parts by mass or more, even more preferably 50 parts by mass or more, and preferably 99 parts by mass or less, more preferably 98 parts by mass or less, and even more preferably 97 parts by mass or less, from the viewpoint of lipid particle stability.

[0022] The content of lysophospholipid relative to the total amount of phospholipid and lysophospholipid in 100 parts by mass of lipid particles of the present disclosure is preferably 1 part by mass or more, more preferably 2 parts by mass or more, even more preferably 3 parts by mass or more, preferably 70 parts by mass or less, more preferably 55 parts by mass or less, and even more preferably 40 parts by mass or less, from the standpoint of lipid particle stability.

[0023] The lipid particles of the present disclosure are amphiphilic due to the presence of a fatty acid moiety, which is a hydrophobic moiety, and a phosphate moiety, which is a hydrophilic moiety, and in aqueous solution, they form a spherical structure with the hydrophilic moiety facing outward. Because they have such a spherical structure, they are particles, and their particle diameters can be measured as particles. Lipid particles of the present disclosure include, for example, amorphous solid lipid particles, liposomes, bicelles, and micelles. Liposomes are spherical with at least one lipid bilayer structure, bicelles are ellipsoidal or flat with at least one lipid bilayer, and micelles are formed of a lipid monolayer (a single lipid layer). The lipid particles of the present disclosure are preferably amorphous solid lipid particles, liposomes, and bicelles, and particularly preferably amorphous solid lipid particles and liposomes.

[0024] The lipid particles are characterized by including ceramide, but can also include other medicinal ingredients. Examples of the medicinal ingredients disclosed herein include ascorbic acid, magnesium ascorbate phosphate, ascorbyl tetrahexyldecanoate, L-ascorbic acid 2-glycoside, allantoin, arbutin, inulin, oleic acid, carotene, carnosine, carnitine, glycyrrhetinic acid, potassium glycyrrhizinate, glutathione, tocopherol acetate, tocopherol, palmitic acid, panthenol, placenta, minoxidil, linolenic acid, retinol, retinol acetate, retinol palmitate, tranexamic acid, lenoleic acid, ubiquinone, extracts derived from plants and animals, and extracts derived from minerals.

[0025] When the lipid particles of the present disclosure have a multi-layer structure, the water-soluble components of the medicinal ingredients and the like can be incorporated between the hydrophilic core portion and the hydrophilic portion of the lipid bilayer membrane, and the oil-soluble components can be incorporated into the hydrophobic lipid bilayer membrane. Furthermore, the medicinal ingredients contained in the lipid particles are retained in the lipid particles, and when they act on the skin, for example, the medicinal ingredients can be sustainedly released inside the skin. The encapsulation ratio of the active ingredient in the lipid particles of the present disclosure is, in terms of water-soluble components in 100 parts by mass of lipid particle solution, preferably 0.001 parts by mass or more and 20 parts by mass or less, more preferably 0.005 parts by mass or more and 15 parts by mass or less, even more preferably 0.01 parts by mass or more and 12.5 parts by mass or less, and even more preferably 0.015 parts by mass or more and 10 parts by mass or less.

[0026] The lipid particles of the present disclosure preferably have a particle diameter of 10 nm or more and 600 nm or less, more preferably 30 nm or more and 500 nm or less, even more preferably 50 nm or more and 400 nm or less, and even more preferably 80 nm or more and 300 nm or less. By having the particle diameter within the above range, the storage stability of the cosmetic composition of the present disclosure, transdermal permeability, and skin barrier property tend to be further improved.

[0027] The lipid particles of the present disclosure preferably have a polydispersity of 0.50 or less, more preferably 0.40 or less, even more preferably 0.30 or less, and even more preferably 0.25 or less. By having a polydispersity within the above range, the storage stability, transdermal permeability, and skin barrier property of the cosmetic composition of the present disclosure tend to be further improved. The cosmetic composition of the present disclosure preferably exhibits a variation rate of the average particle size of ±20% or less after storage for one month at 4°C, 25°C, 40°C, or 50°C, more preferably ±18% or less, even more preferably ±15% or less, and even more preferably ±10% or less. By being within the above range, the cosmetic composition of the present disclosure exhibits excellent long-term storage stability and is commercially useful. The particle size can be measured by the method described in the Examples.

[0028] Regarding the particle size distribution of the lipid particles of the present disclosure, from the viewpoint of aggregation, the abundance ratio of lipid particles of 80 nm to 400 nm is preferably 70 area % to 100 area %, more preferably 75 area % to 99 area %, and even more preferably 80 area % to 98 area %. From the viewpoint of the feel of the lipid particle solution, the abundance ratio of lipid particles of 1000 nm or more is preferably 30 area % or less, more preferably 15 area % or less, and even more preferably 20 area % or less. The abundance ratio of lipid particles of the present disclosure can be calculated from the scattering intensity distribution obtained by cumulant analysis using, for example, FPAR-1000 (manufactured by Otsuka Electronics Co., Ltd.).

[0029] Furthermore, the cosmetic compositions of the present disclosure have a rich texture in addition to the unique feel derived from the lipid particles. Furthermore, they are not sticky or are not sticky at all. Furthermore, the cosmetic compositions of the present disclosure have excellent permeability into the epidermis and dermis. Transdermal permeability, such as permeability into the epidermis and dermis, can be evaluated by applying a solution of lipid particles containing a water-soluble fluorescent dye such as carboxyfluorescein or a carboxyfluorescein derivative, an oil-soluble fluorescent dye such as DiI or DiO, a medicinal ingredient, lipid, or a labeled compound such as a fluorescently labeled substance to a three-dimensional skin model or human skin, and then conducting a skin permeation test. The permeability of the labeled compound can be evaluated by analyzing the solution remaining on the top of the skin or skin model after the permeation test, the solution that has permeated to the bottom, and the skin after the permeation test. The labeled compound in the solution remaining on the top of the skin or skin model after the permeation test and the solution that has permeated to the bottom can be quantified using various methods. After the permeation test, the skin can be evaluated by image analysis of the skin sections to assess the degree of penetration of the labeled compound; by extracting the labeled compound from the collected skin and quantifying it using various analytical techniques; by tape-stripping the collected skin to separate the stratum corneum layer by layer and analyzing the images; or by extracting the labeled compound and quantifying it using various analytical techniques. Image analysis of skin sections can be performed using confocal laser scanning microscopes, fluorescence microscopes, optical microscopes, and small-angle and wide-angle X-ray scattering. Depending on the type of labeled compound, quantification of the labeled compound can be performed using a combination of detection methods such as ultraviolet-visible spectrophotometers, fluorescence spectrophotometers, differential refractive index, mass spectrometry, electrical conductivity, evaporative light scattering, and corona charged particle spectroscopy, along with instruments such as liquid chromatography or gas chromatography, or by using a labeled compound quantification kit.

[0030] The zeta potential of the particle surface of the lipid particles of the present disclosure is a positive or negative value, and the absolute value is preferably greater than 5 mV, more preferably greater than 10 mV, even more preferably greater than 20 mV, and even more preferably greater than 30 mV. When the positive value is within the above range, the transdermal permeability of the cosmetic composition of the present disclosure tends to be further improved. Furthermore, when the negative value is within the above range, the storage stability of the cosmetic composition of the present disclosure tends to be further improved. The zeta potential can be measured by the method described in the Examples.

[0031] The membrane structure of the lipid particles of the present disclosure is in one of the following states: gel, liquid crystal, and amorphous. A lipid particle solution containing a single lipid particle in one of these states has improved fluorescence storage stability compared to a lipid particle solution containing a mixture of lipid particles in one of these states. By uniformly mixing lipid molecules at the molecular level, particles with uniform molecular arrangement are obtained, and the progression of crystallization can be suppressed, resulting in lipid particles with excellent long-term stability. The membrane structure can be measured using the method described in the Examples. The fluorescence anisotropy of the lipid particles of the present disclosure can be measured by incorporating a fluorescent substance into the lipid particles, and the lower the value, the higher the membrane fluidity of the lipid particles. The high membrane fluidity of the lipid particles of the present disclosure tends to promote transdermal permeability and improve the function of replenishing missing areas of intercellular lipids. Fluorescence anisotropy can be measured by the method described in the Examples.

[0032] <Cosmetic composition> A cosmetic composition containing ceramide-containing lipid particles preferably contains water from the viewpoint of use as a cosmetic. In the present disclosure, examples of water include ordinary tap water, ion-exchanged water, pure water, soft water, hard water, natural water, deep-sea water, alkaline ionized water, purified water obtained by various methods, etc. In addition, extracts derived from animals and plants, extracts derived from minerals, etc., or water containing these extracts, can also be used. The water content per 100 parts by mass of the cosmetic composition of the present disclosure is preferably 50 parts by mass or more, more preferably 60 parts by mass or more, and more preferably 70 parts by mass or more, and is preferably 98 parts by mass or less, more preferably 96 parts by mass or less, and more preferably 94 parts by mass or less. Within the above ranges, the storage stability of the cosmetic composition of the present disclosure tends to be further improved. The ceramide-containing lipid particles of the present disclosure may be dispersed in a solution or used as a powder. When used as a powder, the obtained ceramide-containing lipid particle solution may be dried to obtain a powder. The ceramide-containing lipid particles of the present disclosure may be used as a powder and directly added to a cosmetic.

[0033] The content of lipid particles relative to 100 parts by mass of the cosmetic composition of the present disclosure is preferably 0.01 parts by mass or more, more preferably 0.05 parts by mass or more, even more preferably 0.1 parts by mass or more, and is preferably 10 parts by mass or less, more preferably 8 parts by mass or less, and even more preferably 5 parts by mass or less.

[0034] The cosmetic composition of the present disclosure may contain alcohol, but it is not necessary to use alcohol. Alcohols of the present disclosure include monohydric alcohols, dihydric alcohols, trihydric or higher alcohols, and the like.

[0035] Examples of the monohydric alcohol of the present disclosure include linear alcohols such as ethanol, propanol, lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol, lanolin alcohol, behenyl alcohol, and cetostearyl alcohol; branched alcohols such as isopropanol, isobutyl alcohol, t-butyl alcohol, 2-butyl-1-octanol, 2-hexyl-1-decanol, 2-octyl-1-dodecanol, isostearyl alcohol, and 2-decyl-1-tetradecanol; ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, ethylene glycol monophenyl ether, ethylene glycol monohexyl ether, ethylene glycol mono-2-methylhexyl ether, ethylene glycol isoamyl ether, ethylene glycol benzyl ether, and ethylene glycol isopropyl ether. From the viewpoint of lipid solubility, ethanol, propanol, isopropanol, and t-butyl alcohol are preferred, and ethanol is more preferred. Furthermore, from the viewpoint of inhibiting aggregation of lipid particles, monohydric branched alcohols are preferred, 2-octyl-1-dodecanol, isostearyl alcohol and 2-decyl-1-tetradecanol are more preferred, and 2-octyl-1-dodecanol and 2-decyl-1-tetradecanol are even more preferred.

[0036] The dihydric alcohol of the present disclosure is an alcohol having two hydroxyl groups in the molecule, such as ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, 1,3-butylene glycol, 1,2-butanediol, 1,4-butylene glycol, isoprene glycol, 1,2-pentanediol, isopentyldiol, 1,2-hexanediol, 1,2-octanediol, 1,2-decanediol, and dipropylene glycol. From the viewpoint of inhibiting aggregation of lipid particles, 1,3-butylene glycol, 1,2-pentanediol, isopentyldiol, 1,2-hexanediol, 1,2-octanediol, and 1,2-decanediol are preferred, with 1,3-butylene glycol and 1,2-octanediol being more preferred.

[0037] The trihydric or higher alcohols of the present disclosure are alcohols having three or more hydroxyl groups per molecule. Examples of trihydric alcohols include glycerin and trimethylolpropane. Examples of tetrahydric alcohols include pentaerythritol such as 1,2,6-hexanetriol. Examples of pentahydric alcohols include xylitol. Examples of hexahydric alcohols include sorbitol and mannitol. Examples of polyhydric alcohol polymers include diethylene glycol, dipropylene glycol, triethylene glycol, polypropylene glycol, tetraethylene glycol, diglycerin, polyethylene glycol, triglycerin, tetraglycerin, and polyglycerin. Other compounds having two or more hydroxyl groups per molecule include glycerin monoalkyl ether, xyl alcohol, selachyl alcohol, and batyl alcohol. Examples of sugar alcohols include sorbitol, maltitol, maltotriose, mannitol, sucrose, erythritol, glucose, fructose, starch-decomposed sugars, maltose, xylitose, and starch-decomposed sugar-reduced alcohols.

[0038] From the viewpoint of lipid particle stability, the content of monohydric alcohol contained in 100 parts by mass of the cosmetic composition of the present disclosure is preferably 0.01 parts by mass or more, more preferably 0.05 parts by mass or more, and even more preferably 0.1 parts by mass or more, and is preferably 20 parts by mass or less, more preferably 15 parts by mass or less, and even more preferably 10 parts by mass or less.

[0039] The content of dihydric alcohols and trihydric or higher alcohols contained in 100 parts by mass of the cosmetic composition of the present disclosure is preferably 1 part by mass or more, more preferably 2 parts by mass or more, and more preferably 3 parts by mass or more, and preferably 35 parts by mass or less, more preferably 25 parts by mass or less, and more preferably 20 parts by mass or less. Within the above ranges, the storage stability of the cosmetic composition of the present disclosure tends to be further improved. In the cosmetic composition of the present disclosure, the content of the trihydric or higher alcohol per 100 parts by mass of the dihydric alcohol and the trihydric or higher alcohol is preferably 0 to 50 parts by mass, more preferably 0 to 40 parts by mass, and particularly preferably 0 to 30 parts by mass. By being in the above range, the cosmetic composition tends to be less sticky and have an excellent feel when used. In the present disclosure, the content of the dihydric alcohol per 100 parts by mass of the dihydric alcohol and the trihydric or higher alcohol is preferably 50 parts by mass or more, more preferably 60 parts by mass or more, even more preferably 70 parts by mass or more, and particularly preferably 75 parts by mass or more. These polyhydric alcohols can be used alone or in combination of two or more types.

[0040] The cosmetic composition of the present disclosure may contain substances other than phospholipids, cholesterol, lysophospholipids, and ceramides. Examples include thickeners, powder components, pH adjusters, nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, oils, moisturizers, water-soluble polymers, antioxidants, UV absorbers, chelating agents, preservatives, antibacterial agents, colorants, and fragrances. Any substances typically incorporated into cosmetics can be incorporated as appropriate.

[0041] Examples of thickeners include gum arabic, carrageenan, karaya gum, tragacanth gum, carob gum, quince seed, casein, dextrin, gelatin, sodium pectinate, sodium allaginate, methylcellulose, ethylcellulose, CMC, hydroxyethylcellulose, hydroxypropylcellulose, PVA, PVM, PVP, sodium polyacrylate, carboxyvinyl polymer, locust bean gum, guar gum, tamarind gum, dialkyldimethylammonium cellulose sulfate, xanthan gum, aluminum magnesium silicate, bentonite, hectorite, AlMg silicate (Bee Gum), Laponite, and silicic anhydride. Examples of powder components include inorganic powders (e.g., talc, kaolin, mica, sericite, muscovite, phlogopite, synthetic mica, lepidolite, biotite, vermiculite, magnesium carbonate, calcium carbonate, aluminum silicate, barium silicate, calcium silicate, magnesium silicate, strontium silicate, metal tungstate, magnesium, silica, zeolite, barium sulfate, calcined calcium sulfate (calcined gypsum), calcium phosphate, fluorapatite, hydroxyapatite, ceramic powder, metal soap (e.g., zinc myristate, calcium palmitate, aluminum stearate), boron nitride, etc.); organic powders (e.g., polyamide resin powder (nylon powder), polyethylene powder, polymethyl methacrylate powder, polystyrene powder, styrene-acrylic acid copolymer resin powder, benzoguanamine resin powder, polytetrafluoroethylene powder, cellulose powder, etc.); inorganic white pigments (e.g., titanium dioxide, zinc oxide, etc.); inorganic red pigments (e.g., iron oxide (red iron), iron titanate, etc.); inorganic brown pigments (e.g., gamma-iron oxide, etc.); inorganic yellow pigments (e.g., yellow iron oxide, yellow ochre, etc.); inorganic black Color pigments (e.g., black iron oxide, low-order titanium oxide, etc.); inorganic purple pigments (e.g., mango violet, cobalt violet, etc.); inorganic green pigments (e.g., chromium oxide, chromium hydroxide, cobalt titanate, etc.); inorganic blue pigments (e.g., ultramarine, Prussian blue, etc.); pearl pigments (e.g., titanium oxide-coated mica, titanium oxide-coated bismuth oxychloride, titanium oxide-coated talc, colored titanium oxide-coated mica, bismuth oxychloride, fish scale foil, etc.); metal powder pigments (e.g., aluminum powder, copper powder, etc.); zirconium, barium organic pigments such as aluminum or aluminum lakes (e.g., organic pigments such as Red No. 201, Red No. 202, Red No. 204, Red No. 205, Red No. 220, Red No. 226, Red No. 228, Red No. 405, Orange No. 203, Orange No. 204, Yellow No. 205, Yellow No. 401, and Blue No. 404, Red No. 3, Red No. 104, Red No. 106, Red No. 227, Red No. 230, Red No. 401, Red No. 505, Orange No. 205, Yellow No. 4, Yellow No. 5, Yellow No. 202, Yellow No. 203, Green No. 3, and Blue No. 1); natural pigments (e.g., chlorophyll, β-carotene, etc.); and the like.

[0042] Examples of pH adjusters include lactic acid-sodium lactate, citric acid-sodium citrate, succinic acid-sodium succinate, hydroxides of alkali metals (such as sodium and potassium) or alkaline earth metals (such as calcium), ammonia water, citric acid, tartaric acid, lactic acid, phosphoric acid, neutral amino acids (such as threonine and cysteine), basic amino acids (such as hydroxylysine), sodium acyl sarcosine (sodium lauroyl sarcosine), acyl glutamate, sodium acyl-β-alanine, glutathione, and pyrrolidone carboxylic acid.

[0043] Examples of nonionic surfactants include POE (polyoxyethylene) sorbitan fatty acid esters (e.g., POE sorbitan monooleate, POE sorbitan monostearate, POE sorbitan monooleate, POE sorbitan tetraoleate, etc.); POE sorbit fatty acid esters (e.g., POE sorbit monolaurate, POE sorbit monooleate, POE sorbit pentaoleate, POE sorbit monostearate, etc.); POE glycerin fatty acid esters (e.g., POE glycerin monooleate, POE sorbitan ... POE monooleates such as serine monostearate, POE glycerin monoisostearate, and POE glycerin triisostearate; POE fatty acid esters (e.g., POE distearate, POE monodioleate, and ethylene glycol distearate); POE alkyl ethers (e.g., POE lauryl ether, POE oleyl ether, POE stearyl ether, POE-behenyl ether, POE-2-octyldodecyl ether, and POE cholestanol ether); Pluronic (registered trademark) molding agents, etc.; POE·POP alkyl ethers (e.g., POE·POP cetyl ether, POE·POP-2-decyltetradecyl ether, POE·POP monobutyl ether, POE·POP hydrogenated lanolin, POE·POP glycerin ether, etc.); tetraPOE·tetraPOP ethylenediamine condensates (e.g., Tetronic, etc.); POE castor oil hydrogenated castor oil derivatives (e.g., POE castor oil, POE hydrogenated castor oil, POE hydrogenated castor oil monoisostearate, POE hydrogenated castor oil triisostearate, etc.); isostearate, POE hydrogenated castor oil monopyroglutamic acid monoisostearate diester, POE hydrogenated castor oil maleic acid, etc.); POE beeswax and lanolin derivatives (e.g., POE sorbitan beeswax, etc.); alkanolamides (e.g., coconut oil fatty acid diethanolamide, lauric acid monoethanolamide, fatty acid isopropanolamide, etc.); POE propylene glycol fatty acid esters; POE alkylamines; POE fatty acid amides; sucrose fatty acid esters; alkylethoxydimethylamine oxide;Trioleyl phosphate, sorbitan fatty acid esters (e.g., sorbitan monooleate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesquioleate, sorbitan trioleate, diglycerol sorbitan penta-2-ethylhexyl, diglycerol sorbitan tetra-2-ethylhexyl, etc.); glycerin fatty acids (e.g., glycerin monocottonseed oil fatty acid, glycerin monoerucate, glycerin sesquioleate, glycerin monostearate, α,α'-oleic acid pyroglutamic acid glycerin, glycerin monostearate malate, polyglyceryl monoisostearate, polyglyceryl diisostearate, etc.); propylene glycol fatty acid esters (e.g., propylene glycol monostearate, etc.); hydrogenated castor oil derivatives; glycerin alkyl ethers, etc.;

[0044] Examples of anionic surfactants include fatty acid soaps (e.g., sodium laurate, sodium palmitate, etc.); higher alkyl sulfates (e.g., sodium lauryl sulfate, potassium lauryl sulfate, etc.); alkyl ether sulfates (e.g., POE triethanolamine lauryl sulfate, POE sodium lauryl sulfate, etc.); N-acyl sarcosinates (e.g., sodium lauroyl sarcosinate, etc.); higher fatty acid amide sulfonates (e.g., sodium N-myristoyl-N-methyl taurate, sodium coconut oil fatty acid methyl tauride, sodium lauryl methyl tauride, etc.); phosphates (sodium POE oleyl ether phosphate, sodium POE stearyl ether phosphate, etc.); sulfosuccinates (e.g., sodium di-2-ethylhexyl sulfosuccinate, sodium monolauroyl monoethanolamide polyoxyethylene sulfosuccinate, sodium lauryl polypropylene glycol sulfosuccinate, etc.). alkylbenzenesulfonates (e.g., sodium linear dodecylbenzenesulfonate, triethanolamine linear dodecylbenzenesulfonate, linear dodecylbenzenesulfonic acid, etc.); higher fatty acid ester sulfate salts (e.g., sodium hydrogenated coconut oil fatty acid glycerin sulfate, sodium stearoyl methyl taurate, etc.); N-acylglutamates (e.g., monosodium N-lauroylglutamate, disodium N-stearoylglutamate, monosodium N-myristoyl-L-glutamate, etc.); sulfated oils (e.g., turmeric oil, etc.); POE alkyl ether carboxylic acids; POE alkyl allyl ether carboxylates; α-olefin sulfonates; higher fatty acid ester sulfonates; secondary alcohol sulfate salts; higher fatty acid alkylolamide sulfate salts; sodium lauroyl monoethanolamide succinate; N-palmitoyl aspartic acid ditriethanolamine; sodium caseinate; and the like. Examples of cationic surfactants include alkyltrimethylammonium salts (e.g., stearyltrimethylammonium chloride, lauryltrimethylammonium chloride, etc.); alkylpyridinium salts (e.g., cetylpyridinium chloride, etc.); distearyldimethiammonium chloride dialkyldimethylammonium salts; poly(N,N'-dimethyl-3,5-methylenepiperidinium chloride); alkyl quaternary ammonium salts; alkyldimethylbenzylammonium salts; alkylisoquinolinium salts; dialkylmorphonium salts; POE alkylamines; alkylamine salts; polyamine fatty acid derivatives; amyl alcohol fatty acid derivatives; benzalkonium chloride; benzethonium chloride; and the like.

[0045] Examples of amphoteric surfactants include imidazoline-based amphoteric surfactants (e.g., 2-undecyl-N,N,N-(hydroxyethylcarboxymethyl)-2-imidazoline sodium, 2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy disodium salt, etc.); betaine-based surfactants (e.g., 2-heptadecyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, lauryldimethylaminoacetic acid betaine, alkyl betaine, amido betaine, sulfobetaine, etc.); and the like. The oil agent is not particularly limited, but examples thereof include fatty acids, fats and oils, ester oils, silicone oils, and hydrocarbon oils. These components may be used alone or in appropriate combination of two or more. Examples of fatty acids include lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, behenic acid, undecylenic acid, lanolinic acid, and isostearic acid.

[0046] Examples of fats and oils include coconut oil, palm oil, hydrogenated palm oil, avocado oil, sesame oil, olive oil, kukui nut oil, grape kernel oil, safflower oil, almond oil, corn oil, cottonseed oil, sunflower seed oil, grape seed oil, hazelnut oil, macadamia nut oil, meadowfoam oil, and rosehip oil. Examples of ester oils include ethyl oleate, isopropyl myristate, isopropyl palmitate, myristyl myristate, cetyl palmitate, oleyl oleate, octyldodecyl myristate, octyldodecyl oleate, ethyl isostearate, isopropyl isostearate, cetyl 2-ethylhexanoate, cetostearyl 2-ethylhexanoate, glyceryl tri-2-ethylhexanoate, caprylic / capric triglyceride, glyceryl triisopalmitate, pentaerythritol tetra-2-ethylhexanoate, isocetyl octanoate, isostearyl octanoate, isocetyl isostearate, octyldodecyl isostearate, and octyldodecyl dimethyloctanoate.

[0047] Examples of silicone oils include methylpolysiloxane, highly polymerized methylpolysiloxane, methylphenylpolysiloxane, octamethyltrisiloxane, decamethyltetrasiloxane, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, methylcyclopolysiloxane, alcohol-modified silicone, alkyl-modified silicone, amino-modified silicone, and epoxy-modified silicone. Examples of hydrocarbon oils include liquid paraffin, olive squalane, rice squalane, squalane, pristane, white petrolatum, paraffin wax, ozokerite, ceresin, and microcrystalline wax. Examples of moisturizing agents include chondroitin sulfate, hyaluronic acid, mucoitin sulfate, caronic acid, atelocollagen, cholesteryl-12-hydroxystearate, sodium lactate, bile salts, dl-pyrrolidone carboxylate, short-chain soluble collagen, diglycerin (EO)PO adduct, Rosa robur extract, yarrow extract, and melilot extract.

[0048] Examples of water-soluble polymers include plant-based polymers (e.g., gum arabic, tragacanth gum, galactan, guar gum, carob gum, karaya gum, carrageenan, pectin, agar, quince seed (marmella), algae colloid (cassow extract), starch (rice, corn, potato, wheat), glycyrrhizic acid); microbial-based polymers (e.g., xanthan gum, dextran, succinoglucan, pullulan, etc.); animal-based polymers (e.g., collagen, casein, albumin, gelatin, etc.); starch-based polymers (e.g., carboxymethyl starch, methylhydroxypropyl starch, etc.); cellulose-based polymers (methylcellulose, ethylcellulose, methylhydroxypropylcellulose, Hydroxyethyl cellulose, sodium cellulose sulfate, hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, crystalline cellulose, cellulose powder, etc.); alginic acid polymers (e.g., sodium alginate, propylene glycol alginate, etc.); vinyl polymers (e.g., polyvinyl alcohol, polyvinyl methyl ether, polyvinylpyrrolidone, carboxyvinyl polymer, etc.); polyoxyethylene polymers (e.g., polyethylene glycol 20,000, 40,000, 60,000, etc.); acrylic polymers (e.g., sodium polyacrylate, polyethyl acrylate, polyacrylamide, etc.); polyethyleneimine; cationic polymers Examples of antioxidants include tocopherols, dibutylhydroxytoluene, butylhydroxyanisole, and gallic acid esters.

[0049] Examples of the ultraviolet absorber include benzoic acid-based ultraviolet absorbers (e.g., para-aminobenzoic acid (hereinafter abbreviated as PABA), PABA monoglycerin ester, N,N-dipropoxy PABA ethyl ester, N,N-diethoxy PABA ethyl ester, N,N-dimethyl PABA ethyl ester, N,N-dimethyl PABA butyl ester, N,N-dimethyl PABA ethyl ester, etc.); anthranilic acid-based ultraviolet absorbers (e.g., homomenthyl-N-acetylanthranilate, etc.); salicylic acid-based ultraviolet absorbers (e.g., amyl salicylate, etc.); cinnamic acid-based ultraviolet absorbers (e.g., octyl cinnamate, ethyl 4-isopropyl cinnamate, methyl 2,5-diisopropyl cinnamate, ethyl 2,4-diisopropyl cinnamate, methyl 2,4-diisopropyl cinnamate, propyl p-methoxycinnamate, isopropyl p-methoxycinnamate, isoamyl p-methoxycinnamate, methyl 2,5-diisopropyl cinnamate, ethyl 2,4-diisopropyl cinnamate, propyl p-methoxycinnamate, isopropyl p-methoxycinnamate, isoamyl p-methoxycinnamate, methyl 2,5-diisopropyl cinnamate, ethyl 2,4-diisopropyl cinnamate, methyl ...methyl 2,4-diisopropyl cinnamate, methyl 2,5-diisopropyl cinnamate, methyl 2,4-diisopropyl cinnamate, methyl 2,5-diisopropyl cinnamate, methyl 2,4-diisopropyl cinnamate, methyl 2,5-diisopropyl cinnamate, methyl 2,4-diisopropyl cinnamate, methyl 2,5-diisopropyl cinnamate, methyl 2,4-diisopropyl cinnamate, methyl 2,5-diisopropyl cinnamate, methyl 2,5-diisopropyl cinnamate, methyl 2,5-diiso cyclohexyl-p-methoxycinnamate, octyl-p-methoxycinnamate (2-ethylhexyl-p-methoxycinnamate), 2-ethoxyethyl-p-methoxycinnamate, cyclohexyl-p-methoxycinnamate, ethyl-α-cyano-β-phenylcinnamate, 2-ethylhexyl-α-cyano-β-phenylcinnamate, glyceryl mono-2-ethylhexanoyl-di-para-methoxycinnamate, etc.; benzophenone-based ultraviolet absorbers (e.g., 2,4-dihydroxybenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone, etc.); non, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone, 2,2',4,4'-tetrahydroxybenzophenone, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonate, 4-phenylbenzophenone, 2-ethylhexyl-4'-phenyl-benzophenone-2-carboxylate, 2-hydroxy-4-n-octoxybenzophenone, 4-hydroxy-3-carboxybenzophenone, etc.);3-(4'-methylbenzylidene)-d,L-camphor, 3-benzylidene-d,l-camphor; 2-phenyl-5-methylbenzoxazole; 2,2'-hydroxy-5-methylphenylbenzotriazole; 2-(2'-hydroxy-5'-t-octylphenyl)benzotriazole; 2-(2'-hydroxy-5'-methylphenylbenzotriazole; dibenzalazine; dianisoylmethane; 4-methoxy-4'-t-butyldibenzoylmethane; 5-(3,3-dimethyl-2-norbornylidene)-3-pentan-2-one; and the like. Examples of chelating agents include 1-hydroxyethane-1,1-diphosphonic acid, 1-hydroxyethane-1,1-diphosphonic acid tetrasodium salt, edetate disodium, edetate trisodium, edetate tetrasodium, sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid, phosphoric acid, citric acid, ascorbic acid, succinic acid, edetic acid, and ethylenediaminehydroxyethyltriacetate trisodium salt. Examples of preservatives and antibacterial agents include parabens such as ethylparaben, isopropylparaben, butylparaben, and benzylparaben, and their sodium salts, benzoic acid, benzoates, alkyldiaminoethylglycine hydrochloride, photosensitizers, chlorcresol, chlorobutanol, salicylic acid, salicylates, sorbic acid and its salts, dehydroacetic acid and its salts, trichlorohydroxydiphenyl ether (also known as triclosan), phenoxyethanol, phenol, sodium lauryldiaminoethylglycine, resorcinol, zinc, ammonia, Examples of suitable antiperspirants include silver complex-substituted zeolite, pantothenyl ethyl ether benzoate, isopropyl methylphenol, cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, chlorhexidine hydrochloride, orthophenylphenol, sodium orthophenylphenol, silver-copper zeolite, chlorhexidine gluconate, cresol, chloramine T, chloroxylenol, chlorphenesin, chlorhexidine, 1,3-dimethylol-5,5-dimethylhydantoin, alkylisoquinolinium bromide, thianthol, and thymol. Examples of fragrances include terpenes and terpenoids such as citral, menthol, camphor, salvinorin A, cannabinoids, hinokitiol, limonene, farnesol, and vitamin A; aromatic alcohols such as phenoxyethanol; phenols such as eugenol and shogaol; esters such as butyrate esters and propionate esters; lactones such as γ-nonalactone and γ-undecalactone; and aldehydes having 6 to 20 carbon atoms.

[0050] The content of other constituent substances is preferably 0% by mass or more and 20% by mass or less, and more preferably 0% by mass or more and 10% by mass or less. One type of other constituent substance can be used, or two or more types can be mixed together.

[0051] <Method of manufacturing a cosmetic composition> The method for producing the cosmetic composition of the present disclosure is not particularly limited. Preferably, the production includes a step of mixing a composition containing phospholipids, a polyhydric alcohol, water, and, if necessary, a medicinal ingredient (hereinafter also referred to as a "mixing step"). The mixing step may be performed using a dispersing machine with a mechanical stirring structure such as a homogenizer, but is preferably performed using a device with a flow path structure (also referred to as a flow path structure), such as a microflow device. Production using a microflow device tends to further improve the storage stability of the cosmetic composition of the present disclosure. The microflow device is not particularly limited, but examples include the devices described in WO 2018 / 190423, WO 2018 / 123883, JP 2013-255912, and WO 2021 / 075003. The microflow device is preferably a micromixer that mixes two or more liquids, and the micromixer is preferably a baffle mixer such as that described in WO 2018 / 190423. A micromixer has a structure that promotes the mixing or dilution of liquids passing through a microchannel. Among them, a baffle mixer has a structure in which baffles are arranged in a micro-sized channel, and is particularly suitable for controlling the dilution rate, making it highly versatile. Typically, in the above-mentioned mixing / dilution step, phospholipids self-assemble to form lipid particles, but this is not particularly limited. The above-mentioned mixing / dilution step may be performed at room temperature, or under heated or cooled conditions. The above-mentioned mixing / dilution step may be performed under normal pressure, elevated pressure, or reduced pressure. In addition to the above-mentioned mixing / dilution step, the production method of the present disclosure may include other steps such as a purification step, a concentration step, and a further dilution step.

[0052] When using the ceramide-containing lipid particles of the present disclosure as a powder, the obtained ceramide-containing lipid particle solution may be dried to obtain a powder. Examples of the drying method of the present disclosure include freeze drying, vacuum drying, natural drying, spray drying, flash distillation, etc., and freeze drying is more preferable. It may be dried in combination with a general concentration method. As a general concentration method, distillation methods such as atmospheric distillation, vacuum distillation, molecular distillation, and flash distillation can also be used. Membrane separation methods such as ultrafiltration and centrifugation can also be used.

[0053] <Uses such as cosmetic compositions, etc.> The cosmetic composition, etc. of the present disclosure has less stickiness, excellent usability, and excellent long-term storage stability, so it can be preferably applied to skin cosmetics, external skin preparations, etc. In the present disclosure, "for cosmetics" means cosmetics, quasi-drugs, and pharmaceuticals that are directly applied to the human skin, and cosmetics include skin cosmetics, external skin preparations, hair cosmetics, external hair preparations, etc. The cosmetic composition, etc. in the present disclosure is used for the above uses, etc. The cosmetic composition may be used as a cosmetic as it is, or may be used as a cosmetic additive (raw material for cosmetics).

Examples

[0054] Examples are given below to explain the present invention in more detail, but the present invention is not limited to only these examples. Unless otherwise specified, "parts" means "parts by mass" and "%" means "% by mass". <pH measurement> The lipid particle solution described in the examples was measured with a pH electrode 9615S (manufactured by Horiba, Ltd.). <Viscosity measurement> The lipid particle solution described in the examples was measured at 25 °C with a VISOCOMETER BMII type (manufactured by Toki Sangyo Co., Ltd.). <Measurement of average particle diameter and polydispersity> Dynamic light scattering was performed using an FPAR-1000 (Otsuka Electronics Co., Ltd.), and the particle diameter obtained from the Einstein-Stokes equation was used as the average particle diameter. Polydispersity was obtained from cumulant analysis. The lipid particle solution described in the Examples was diluted 100 times with pure water, and the lotion formulation of the Examples was diluted 100 times with pure water. Both were incubated in a 25°C thermostatic bath for 30 minutes, and then measured at 25°C.

[0055] <Zeta potential measurement> The lipid particle solution described in the Examples was diluted 100-fold with pure water and kept in a 25°C thermostatic bath for 30 minutes, and then measured at 25°C using a Zetasizer Nano ZSP (Malvern Instruments). <Storage at various temperatures> The lipid particle solution described in the Examples was filled into a 30 mL glass container and stored at 4°C, 25°C, and 50°C for a certain period of time. <Appearance> The appearance of the lipid particle solution and the formulation was checked, and a homogeneous state without precipitation or deposition was marked as ◯, and an inhomogeneous state was marked as x. <Electron microscope observation> A cryo-electron microscope, TITAN (Thermo Fisher Scientific, accelerating voltage 300 kV), was used. Sample pretreatment was performed using ice embedding with a VITROBOT (Thermo Fisher Scientific). Pretreatment methods for electron microscopy observation are not limited to ice embedding; negative staining and freeze-fracture methods can also be used. Observation kits such as Hitachi High-Tech's K-kit can also be used.

[0056] -Usability evaluation- Using the lipid particle solutions or blended compositions obtained in each example, a test was conducted on subjects to evaluate the feel of the product in use, including smoothness, compatibility with the skin, richness, refreshing sensation, long-lasting moisturizing effect, firmness, and other characteristic sensations. <Smoothness> When the applied solution was spread, it was marked as ◯ if it spread smoothly, evenly, did not catch on anything, and spread well, and if it felt like it caught on anything or was tight, it was marked as x. <Skin compatibility> When the applied solution felt like it was sticking to the skin, it was marked as ◯, and when it did not feel like it was sticking to the skin, it was marked as ×. <Richness> The case where the unique texture of lipid particles was felt was marked as ◯, and the case where the unique texture was not felt was marked as ×. <Refreshing feeling> If there was a cooling sensation when applied, it was rated as "yes," and if there was no cooling sensation, it was rated as "no." <Long-lasting moisturizing> If the skin felt moisturized one hour after application, it was marked as ◯, and if no moisturizing feeling remained, it was marked as ×. <Sustained smoothness> If the skin felt as smooth one hour after application as it did immediately after application, it was marked as ◯, and if the skin did not feel as smooth as it did immediately after application, it was marked as ×. <Sustained firmness> If you felt a soft elasticity pushing back from the inside of your skin after one hour of application, you were marked with a "yes," and if you did not feel any soft elasticity, you were marked with an "x." <Quantitative determination of caffeine> The analysis was performed using a liquid chromatograph (Shimadzu) and a column (Capdell Pak C18 SG120, 4.6 mm I.D. x 250 mm, Osaka Soda). A calibration curve was prepared in advance using caffeine solutions of known concentrations. UV: 254 nm Developer: Water: Methanol: Sase A = 39:60:1 (vol / vol) Flow rate: 0.8ml / min

[0057] [Example 1] A lipid solution (solution 1) prepared by dissolving 7.2 parts of Phospholipon 90H (manufactured by Lipoid), 1.5 parts of Cholesterol NF-PW-(JP) (manufactured by Croda Japan Co., Ltd.), 1.2 parts of SLP-PC70HS (manufactured by Tsuji Oil Mills Co., Ltd.), and 3.0 parts of Ceramide NG (manufactured by Takasago International Corporation) in 43.2 parts of 1,3-butanediol (manufactured by Daicel Corporation) and 43.2 parts of ethanol (manufactured by Japan Alcohol Industry Co., Ltd.) was mixed with 496.5 parts of water (solution 2) in a baffle mixer-type flow path structure to prepare a lipid particle solution. [Examples 2 to 11, Comparative Examples 1 to 9] A lipid particle solution was prepared in the same manner as in Example 1, except that the raw materials listed in Table 1 were used and the formulations were changed to those listed in Tables 2 to 4.

[0058] [Table 1]

[0059] [Table 2]

[0060] [Table 3]

[0061] [Table 4]

[0062] - Stability of lipid particle solutions - Various evaluations were carried out on the lipid particle solutions obtained in Examples 1 to 11 and Comparative Examples 1 to 9. The results are shown in Tables 5 to 7.

[0063] [Table 5]

[0064] [Table 6]

[0065] [Table 7]

[0066] The results in Tables 5 to 7 show that the lipid particle solutions of Examples 1 to 11 of the present invention maintained the particle size, polydispersity, coarse particle content, pH, and appearance immediately after preparation even after storage at various temperatures, and maintained a uniform state without precipitation or deposition, demonstrating excellent storage stability.

[0067] <Blend composition> Formulations containing the lipid particle solutions obtained in Examples 1, 7, and Comparative Example 1 (formulations 1 to 5) and formulations containing no lipid particle solution (formulations 6 and 7) were formulated according to the compositions shown in Table 8. All formulations were homogeneous with no precipitation or sedimentation, and were in a state worthy of evaluation for storage stability and texture.

[0068] [Table 8]

[0069] -Physical properties and stability of blended compositions- Immediately after preparation, no precipitation or deposition was observed in Blended Compositions 1 to 7, and they were homogeneous. Table 9 shows the physical properties and storage stability of the resulting blended compositions.

[0070] [Table 9] The results in Table 9 demonstrate that formulations 1 to 3 containing the lipid particle solution of the present invention have excellent long-term stability at both low and high temperatures. Furthermore, the results for formulation 3 demonstrate that compositions without a thickener have excellent storage stability. On the other hand, formulation 4 showed an increase in the proportion of coarse particles after a storage period of one month, indicating poor storage stability. This is because the inclusion of an appropriate amount of lysophospholipid allows for uniform control of the membrane components' alignment at the molecular level and particle curvature, resulting in particles with a stable membrane structure. Additionally, the absolute value of the zeta potential is improved, resulting in improved dispersion stability.

[0071] -Tactile evaluation- Appropriate amounts of Examples 1 and 7 shown in Table 2 and Blended Compositions 1 to 7 shown in Table 8 were applied to the back of the hand, and then the smoothness during application, compatibility with the skin, richness, refreshing effect, duration of moisturizing after application, and duration of firmness were evaluated. The results of the texture evaluation are shown in Tables 10 and 11.

[0072] [Table 10]

[0073] [Table 11]

[0074] <Electron microscope observation> The lipid particles of Example 1 were pretreated by the ice embedding method and observed under a transmission electron microscope. The resulting image is shown in Figure 1. The results in FIG. 1 show that the lipid particles contained in the lipid particle solution of the present invention are spherical.

[0075] <Preparation of lipid particle solution for skin barrier evaluation test using three-dimensional skin model> A lipid particle solution was prepared in the same manner as in Example 1, except that the raw materials listed in Table 1 were used and the formulation was changed to that listed in Table 12.

[0076] [Table 12] The Tris buffer solution shown in Table 12 is a pH 7.5 solution in which 0.1 M sodium chloride is dissolved in a 20 mM aqueous solution of trishydroxymethylaminomethane hydrochloride (hereinafter referred to as Tris buffer solution). The lipid particle solution obtained in Example 12 had an average particle size of 210 nm and a polydispersity of 0.19. The lipid particle solution obtained in Comparative Example 10 had an average particle size of 198 nm and a polydispersity of 0.20.

[0077] <Skin barrier evaluation test using a three-dimensional skin model> A skin barrier property evaluation test was conducted using the lipid particle solutions prepared in Example 12 and Comparative Example 10 as sample solutions. A three-dimensional skin model was used: T-Skin (a reconstructed human full-thickness skin model) sold by Nicoderm Research Co., Ltd. (hereinafter, Nicoderm). A three-dimensional skin model was cut out from the bottom of the T-Skin transwell. As shown in Figure 2, a three-dimensional skin model 4 was sandwiched between vertical Franz diffusion cells 7 (effective diffusion area: 1.13 cm2) with the dermis side facing the receiver liquid 1, and sample solution 5 was applied to the epidermis layer side of the three-dimensional skin model 4. In Figure 2, the constant-temperature circulating water inlet 2 and the constant-temperature circulating water outlet 3 are connected to a thermostatic bath. Warm water at a constant temperature of 37°C was flowed from the constant-temperature circulating water inlet 2 to the constant-temperature circulating water outlet 3 and circulated around the periphery of the vertical Franz diffusion cell 7. The application volume of each sample solution was 1 mL per 1 cm2 of effective diffusion area. 3.7 mL of Tris buffer solution (pH 7.5) was used as the receiver fluid. During the test, receiver fluid 1 was stirred by rotating a stirrer bar 6 placed in receiver fluid 1 with a magnetic stirrer 8. The skin barrier property evaluation test was conducted in a laboratory at a room temperature of 25°C and a humidity of 60%. 120 minutes after application of each sample solution, the applied sample solution was removed, and a 10 mg / mL Tris buffer solution (pH 7.5) containing caffeine (Fujifilm Wako Pure Chemical Industries) was applied. 30, 120, and 240 minutes after application of the caffeine solution, 0.25 mL of receiver fluid was sampled. After each sampling, 0.25 mL of fresh Tris buffer solution (pH 7.5) was added to each receiver phase. The receiver fluid obtained at each sampling time was diluted 3 to 10 times with Tris buffer solution, and the amount of caffeine in the solution was quantified by liquid chromatography. The results are shown in Figure 3. Since the amount of caffeine in the receiver fluid of the lipid particle solution test area containing no ceramide was greater than the cumulative amount of caffeine permeated in the receiver fluid of the lipid particle solution test area containing ceramide, it is thought that applying the lipid particle solution containing ceramide reduced the amount of caffeine permeated by the subsequently applied caffeine, thereby improving the barrier properties of the three-dimensional skin model.

Claims

1. A cosmetic composition comprising ceramide-containing lipid particles that contain a phospholipid, cholesterol, a lysophospholipid, and a ceramide, the ceramide-containing lipid particles having a volume average particle size of 10 nm or more and 600 nm or less and a polydispersity index of 0.50 or less, the content of ceramide per 100 parts by mass of the lipid particles is 1 part by mass or more and 40 parts by mass or less, The cosmetic composition contains a polyhydric alcohol, and the amount of a trihydric or higher alcohol is 20 parts by mass or less per 100 parts by mass of the polyhydric alcohol.

2. 2. A cosmetic composition comprising the ceramide-containing lipid particles according to claim 1, wherein the content of the lysophospholipid per 100 parts by mass of the lipid particles is 0.1 parts by mass or more and 30 parts by mass or less.

3. A cosmetic composition comprising ceramide-containing lipid particles according to claim 1 or 2, wherein the mass ratio of phospholipids to lysophospholipids in the ceramide-containing lipid particles (mass of phospholipids / mass of lysophospholipids) is 0.1 / 1 to 40 / 1.

4. 4. A cosmetic composition comprising ceramide-containing lipid particles according to any one of claims 1 to 3, wherein the content of the lipid particles is 0.01 parts by mass or more and 10 parts by mass or less per 100 parts by mass of the lipid particle-containing cosmetic composition.

5. A cosmetic or cosmetic quasi-drug comprising a cosmetic composition containing the ceramide-containing lipid particles according to any one of claims 1 to 4.

6. A method for producing the cosmetic composition according to any one of claims 1 to 4, which is produced using a flow path structure having two or more flow paths.

Images